Oslo, Norway, May 6, 2026 - Lytix Biopharma ASA ("Lytix" or the "Company") today
announced that new Phase II clinical data on ruxotemitide, also known as VP-315,
will be presented by its partner Verrica Pharmaceuticals Inc. ("Verrica") at the
2026 Society for Investigative Dermatology SID) Annual Meeting, taking place May
13-16, 2026, in Chicago, Illinois.

The data suggests a potential abscopal effect of VP-315 in the treatment of
basal cell carcinoma (BCC), as evidenced by reductions in the size of untreated,
non-injected lesions.

The Phase II data to be presented by Verrica showed:
o	14 untreated non-target lesions in 9 subjects demonstrated an overall 67%
reduction in lesion size following treatment of treated lesions
o	Reductions ranged from 50-100% in superficial lesions and 25-100% in nodular
lesions
o	Complete histologic clearance was observed in 21% of non-target lesions,
corresponding to 3 of 14 lesions
o	Reductions in tumor size were observed in all non-target lesion locations,
including proximal, distal and contralateral to treated lesions
o	No skip lesions were observed
o	Non-serious local skin reactions were reported in 1 non-target lesion

The findings suggest that the therapeutic effects of VP-315 extended beyond
treated lesions. Reductions in untreated non-target lesions suggest a potential
abscopal effect consistent with broader immune activation within the tumor
microenvironment of remote non-target lesions.

"These new data from Verrica further support the unique immune-activating
mechanism of ruxotemitide," said Øystein Rekdal, PhD, CEO of Lytix Biopharma.
"The observed reductions in untreated non-target lesions are highly relevant to
the broader clinical rationale for ruxotemitide, including its potential to
target the cancer disease beyond the injected lesion."

The SID data build on prior findings from Verrica's Phase II BCC study, which
has further validated ruxotemitide's two-step mode of action:
1.	Direct tumor cell disruption with release of tumor antigens and danger
signals.
2.	Subsequent immune activation, converting "cold or immunosuppressed" tumors
into "hot," immune-responsive lesions.

The data also support Lytix's broader development strategy for ruxotemitide,
including treatment settings where local tumor destruction and immune activation
before surgery or other definitive intervention may provide meaningful clinical
value.

Verrica is advancing VP-315 toward pivotal Phase III studies in BCC, while Lytix
continues its broader oncology development strategy for ruxotemitide, including
the NeoLIPA Phase II study in neoadjuvant melanoma with top line results
expected 2H 2026.

Presentation details:
Poster title: VP-315 Demonstrates a Potential Abscopal Effect in Untreated
Non-Target Basal Cell Carcinoma (BCC) Lesions
Poster number: LB1190
Category: Non-Melanoma Cancers and UV Biology/Injury
Presenter: Noah Rosenberg, M.D., Chief Medical Officer, Verrica Pharmaceuticals
Poster session: Friday, May 15, 2026, 4:30 p.m.-6:00 p.m.
Location: Salons B, C, D - Lower Level, Hilton Chicago

About ruxotemitide
Ruxotemitide is an investigational, first-in-class, oncolytic immunotherapy
administered intratumorally, to disrupt tumor cell membranes, release tumor
antigens, and activate local and systemic anti-tumor immune responses
irrespective of tumor heterogeneity or PD-L1 status. Ruxotemitide is being
studied in various tumor settings, including as a neoadjuvant therapy in
resectable solid tumors, both as a monotherapy and in combination therapies.

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide, formerly LTX-315, is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.
Visit www.lytixbiopharma.com.

For further information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com